We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Industry Insights

The Search Begins: Urinary Biomarkers that Indicate Pulmonary Exacerbation in Cystic Fibrosis
Industry Insight

A clinical trial has been launched to identify urine-based biomarkers which indicate lung flare-ups in cystic fibrosis. Researchers believe point-of-care monitoring will help people get treatment faster, improve patient outcomes and reduce healthcare costs.

Read More

Single Cell Analysis with the BD AbSeq Assay
Industry Insight

New tools are enabling researchers to explore individual cells with unprecedented clarity, allowing RNA and protein expression levels to be simultaneously analyzed. In this blog, Brian Lilhanand, Global Platform Leader, Single Cell Multiomics, at BD, discusses how BD’s new AbSeq Assay can provide this targeted profiling and benefit immunology researchers.





Read More

A Move Towards Precise Management of Bacterial Infections
Industry Insight

Following the recent FDA approval of a procalcitonin assay, we spoke with a representative from Fujirebio Diagnostics, Inc. to learn how measuring this important biomarker will improve the healthcare landscape.

Read More

Determining Prognostic Significance of Biomarkers for Risk Stratification of Early Stage Lung Cancer
Industry Insight

During this year’s AACR Annual Meeting we spoke to Dr. Delphine Lissa and Dr. Ana Robles from the National Cancer Institute to learn more about the team’s most recent study on the use of two specific biomarkers for risk stratification of stage I lung cancer patients.

Read More

Accelerating Proteome Analysis With PASEF: A Unique and Sensitive Technique
Industry Insight

Understanding the proteome is a fundamental challenge of biology. Here, Bruker Daltonics' Gary Kruppa and Scarlet Koch outline a new method, Parallel Accumulation Serial Fragmentation (PASEF) that offers faster, more sensitive and more robust proteome analysis, giving scientists the potential to discover low-level, biologically significant proteins and validate them in research.

Read More

A New Generation of Flow Cytometers Advances Multiomics
Industry Insight

Flow cytometry allows the analysis of physical and biochemical features of cells. Advances in machine that can characterize and sort cells will allow researchers to look deeper than ever before into the proteome and transcriptome. We talk with Bob Balderas, VP Market Development at BD on how the cutting-edge machines like the FACSymphony S6 cell sorter incorporate new technology and advance multiomics research.

Read More

How Native MS and Charge Algorithms Can Improve Protein Analysis
Industry Insight

Native Mass Spectrometry (MS) can be used to examine proteins in their natural, folded forms. In this blog, Marshall Bern, Ph.D., the Vice President of Research and Co-Founder of Protein Metrics, discusses how advances in this technique are being paired with cutting-edge charge deconvolution algorithms to improve analysis of antibodies and plasma glycoproteins.

Read More

Cinderella and Mass Spectrometry: Insightful Multi-Dimensional Data Analysis
Industry Insight

Proteomics is a powerful technology for analyzing low-abundance proteins for disease research. But it’s stalled by imprecise and often irreproducible data analysis. Here, David Chiang, Founder of Sage-N Research, explains how his company uses multidimensional separation to improve peptide identification in MS/MS.

Read More

Newly Discovered Biomarker Could Help Diagnose Hearing Loss Earlier
Industry Insight

In collaboration with UConn, Sensorion have identified the first potential biomarker for noise-induced hearing loss, findings which were recently presented at the 53rd American Neurotology Society Annual Spring Meeting.

Read More

Data-Independent Acquisition: A Superior Technique in Mass Spectrometry?
Industry Insight

Whilst Mass Spectrometry is undoubted in its status as a central part of the proteomics toolkit, there is still debate about the way that MS data should be acquired and analyzed. Here, we talk to Florian Marty, Director Global Product Support at Biognosys AG, about why he believes that data-independent acquisition is a superior acquisition technique.

Read More

 
Advertisement